恒瑞医药：SHR-1894注射液获批开展临床试验

Core Viewpoint - Heng Rui Medicine (01276.HK) announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for SHR-1894 injection, a self-developed biological product aimed at treating atopic dermatitis [1] Group 1: Clinical Trial Approval - The NMPA issued a clinical trial approval notice for SHR-1894 injection, allowing the company to commence clinical trials shortly [1] - The approval was based on the review conducted under the Drug Administration Law of the People's Republic of China, confirming that SHR-1894 injection meets the requirements for drug registration [1] Group 2: Product Development - SHR-1894 injection is expected to protect the skin barrier and suppress inflammation during the treatment of atopic dermatitis [1] - Currently, there are no similar drugs approved for market release domestically or internationally [1] - The total research and development investment for the SHR-1894 injection project has reached approximately 40.1 million yuan (unaudited) [1]